That the Red Sox would have one of the best all-around players in baseball in their outfield this season wasn’t unexpected. That it proved to be Ceddanne Rafaela, and not Roman Anthony, is the ...
About half a year into his tenure as GSK’s CEO, Luke Miels is launching a three-year restructuring to navigate the British pharma through upcoming patent cliffs and achieve over 40 billion pounds ...
GSK GSK-1.07%decrease; down pointing triangle shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough that showed limited efficacy in late-stage ...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would ...
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion. The acquisition could help GSK offset a drop in revenue expected ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...
GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC). That deal, signed back in 2022, centered on XMT ...
LONDON, April 12 (Reuters) - British drugmaker GSK's (GSK.L), opens new tab experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after ...
More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results